Skip to main content
Premium Trial:

Request an Annual Quote

Akonni Biosystems Raises $4M

NEW YORK (GenomeWeb) – Akonni Biosystems announced today that it has raised $4 million in bridge financing from its current investors.

The company said the funding will be used to "accelerate key corporate objectives" including preparing a US Food and Drug Administration submission for a clinical IVD pharmacogenomic test for its TruDx 2000 microarray platform; listing its automated sample prep instrument with the FDA as a Class I device; and ramping up development of the TruDx 3000 fully integrated sample-to-answer system, which is slated to enter preclinical testing in 2018.

Akonni said that it also intends to use the money to bring its manufacturing facilities and processes under cGMP compliance and achieve ISO13485 certification, as well as to work with collaborators to expand its test menu.

Akonni has collaborated with a number of institutions to evaluate its technology including Harvard University in tuberculosis and the New York State Department of Health's Wadsworth Center on encephalitis and meningitis.

Akonni added that it is further preparing for an institutional financing round to be led by Greenwich, Connecticut-based investment bank MM Dillon, but provided no additional financial details.

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.